The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.
Open accessAbstract
Increasing evidence suggests that angiotensin II (AngII) acts as a modulator for ventricular remodeling after myocardial infarction. Using competitive reverse-transcriptase polymerase chain reaction, nuclear runoff, and binding assays, we examined the regulation of AngII type 1a and 1b (AT1a-R and AT1b-R) and type 2 receptor (AT2-R) expression in the infarcted rat heart as well as the effects of AngII receptor antagonists. AT1a-R mRNA levels were increased in the infarcted (4.2-fold) and noninfarcted portions (2.2-fold) of the myocardium 7 d after myocardial infarction as compared with those in sham-operated controls, whereas AT1b-R mRNA levels were unchanged. The amount of detectable AT2-R mRNA increased in infarcted (3.1-fold) and noninfarcted (1.9-fold) portions relative to that in the control. The transcription rates for AT1a-R and AT2-R genes, determined by means of a nuclear runoff assay, were significantly increased in the infarcted heart. The AngII receptor numbers were elevated (from 12 to 35 fmol/mg protein) in the infarcted myocardium in which the increases in AT1-R and AT2-R were 3.2- and 2.3-fold, respectively, while the receptor affinity was unchanged. Therapy with AT1-R antagonist for 7 d reduced the increase in AT1-R and AT2-R expressions in the infarcted heart together with a decrease in blood pressure, whereas therapy with an AT2-R antagonist did not affect mRNA levels and blood pressure. Neither AT1-R nor AT2-R antagonists affected the infarct sizes. These results demonstrated that myocardial infarction causes an increase in the gene transcription and protein expression of cardiac AT1a-R and AT2-R, whereas the AT1b-R gene is unaffected, and that therapy with an AT1-R antagonist, but not with an AT2-R antagonist, is effective in reducing the increased expression of AngII receptor subtypes induced by myocardial infarction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911 · cited 1×
“The renin-angiotensin system is activated after acute myocardial infarction and angiotensin I-converting enzyme (ACE)' inhibitors improve the clinical condition of patients after myocardial infarction (6, 7).”
BackgroundPfeffer, M. A., & Braunwald, E. (1990) · Circulation · doi:10.1161/01.cir.81.4.1161 · Cited by 2,877
Wall stress and patterns of hypertrophy in the human left ventricle.
Grossman, W., Jones, D., & McLaurin, L. P. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108079 · Cited by 2,403 · cited 2×
“The myocardial hypertrophy exhibits characteristics of combined pressure and volume overload (4, 5).”
BackgroundWeber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,027
Angiotensin II receptors and angiotensin II receptor antagonists.
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., & Smith, R. D. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00446-6 · Cited by 1,853
Sadoshima, J., & Izumo, S. (1993) · Circulation Research · doi:10.1161/01.res.73.3.413 · Cited by 1,427
Sadoshima, J.-I., Xu, Y., Slayter, H. S., & Izumo, S. (1993) · Cell · doi:10.1016/0092-8674(93)90541-w · Cited by 1,348
Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
Murphy, T. J., Alexander, R. W., Griendling, K. K., Runge, M. S., & Bernstein, K. E. (1991) · Nature · doi:10.1038/351233a0 · Cited by 1,252
Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction
Pfeffer, M. A., Lamas, G. A., Vaughan, D. E., Parisi, A. F., & Braunwald, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807143190204 · Cited by 1,103
Identification of angiotensin II receptor subtypes
Chiu, A. T., Herblin, W. F., McCall, D. E., Ardecky, R. J., Carini, D. J., Duncia, J. V., Pease, L. J., Wong, P. C., Wexler, R. R., Johnson, A. L., et al. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91054-1 · Cited by 819
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Molecular Mechanisms of Myocardial Remodeling
SWYNGHEDAUW, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.1.215 · Cited by 1,460
Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor gene in mice
Hein, L., Barsh, G. S., Pratt, R. E., Dzau, V. J., & Kobilka, B. K. (1995) · Nature · doi:10.1038/377744a0 · Cited by 742
Nakajima, M., Hutchinson, H. G., Fujinaga, M., Hayashida, W., Morishita, R., Zhang, L., Horiuchi, M., Pratt, R. E., & Dzau, V. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10663 · Cited by 680
Liu, Y. H., Yang, X. P., Sharov, V. G., Nass, O., Sabbah, H. N., Peterson, E., & Carretero, O. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119360 · Cited by 603
Goette, A., Staack, T., Röcken, C., Arndt, M., Geller, J. C., Huth, C., Ansorge, S., Klein, H. U., & Lendeckel, U. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00611-2 · Cited by 583
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Extracellular Matrix Remodeling in Heart Failure: A Role for De Novo Angiotensin II Generation
Weber, K. T. (1997) · Circulation · doi:10.1161/01.cir.96.11.4065 · Cited by 557
The role of the renin-angiotensin system in the development of cardiovascular disease
Unger, T. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02321-9 · Cited by 515
Angiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Pathophysiological Role of Angiotensin II Type 2 Receptor in Cardiovascular and Renal Diseases
Matsubara, H. (1998) · Circulation Research · doi:10.1161/01.res.83.12.1182 · Cited by 478
Self-citationRecent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System
Horiuchi, M., Akishita, M., & Dzau, V. J. (1999) · Hypertension · doi:10.1161/01.hyp.33.2.613 · Cited by 473
Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function
KASCHINA, E., & UNGER, T. (2003) · Blood Pressure · doi:10.1080/08037050310001057 · Cited by 458
Role of the Angiotensin Type 2 Receptor in the Regulation of Blood Pressure and Renal Function
Carey, R. M., Wang, Z.-Q., & Siragy, H. M. (2000) · Hypertension · doi:10.1161/01.hyp.35.1.155 · Cited by 431
The renin-angiotensin-aldosterone system: a specific target for hypertension management
Weir, M. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00103-x · Cited by 407
Lenkei, Z., Palkovits, M., Corvol, P., & Llorens-Cortès, C. (1997) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1997.0155 · Cited by 406
Paradis, P., Dali-Youcef, N., Paradis, F. W., Thibault, G., & Nemer, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.931 · Cited by 382
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Horiuchi, M., Hayashida, W., Kambe, T., Yamada, T., & Dzau, V. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.19022 · Cited by 295
Angiotensin receptors: distribution, signalling and function
DINH, D. T., FRAUMAN, A. G., JOHNSTON, C. I., & FABIANI, M. E. (2001) · Clinical Science · doi:10.1042/cs1000481 · Cited by 268
Angiotensin AT2 receptor protects against cerebral ischemia‐induced neuronal injury
Li, J., Culman, J., Hörtnagl, H., Zhao, Y., Gerova, N., Timm, M., Blume, A., Zimmermann, M., Seidel, K., Dirnagl, U., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2960fje · Cited by 266
Kaschina, E., Grzesiak, A., Li, J., Foryst-Ludwig, A., Timm, M., Rompe, F., Sommerfeld, M., Kemnitz, U. R., Curato, C., Namsolleck, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.784868 · Cited by 261
Masaki, H., Kurihara, T., Yamaki, A., Inomata, N., Nozawa, Y., Mori, Y., Murasawa, S., Kizima, K., Maruyama, K., Horiuchi, M., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1885 · Cited by 260
Self-citationThe AT2 receptor—A matter of love and hate
Steckelings, U. M., Kaschina, E., & Unger, T. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.010 · Cited by 257
Pressure Overload Induces Cardiac Hypertrophy in Angiotensin II Type 1A Receptor Knockout Mice
Harada, K., Komuro, I., Shiojima, I., Hayashi, D., Kudoh, S., Mizuno, T., Kijima, K., Matsubara, H., Sugaya, T., Murakami, K., et al. (1998) · Circulation · doi:10.1161/01.cir.97.19.1952 · Cited by 254
Self-citationTsutsumi, Y., Matsubara, H., Ohkubo, N., Mori, Y., Nozawa, Y., Murasawa, S., Kijima, K., Maruyama, K., Masaki, H., Moriguchi, Y., et al. (1998) · Circulation Research · doi:10.1161/01.res.83.10.1035 · Cited by 241
Self-citationThe Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target
Steckelings, U. M., Widdop, R. E., Sturrock, E. D., Lubbe, L., Hussain, T., Kaschina, E., Unger, T., Hallberg, A., Carey, R. M., & Sumners, C. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000281 · Cited by 97
Wilms, H., Rosenstiel, P., Unger, T., Deuschl, G., & Lucius, R. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505040-00004 · Cited by 52
Metadata
- Authors
- Nio, Y., Matsubara, H., Murasawa, S., Kanasaki, M., & Inada, M.
- Venue
- Journal of Clinical Investigation
- Published
- 1995-01-01
- Volume
- 95
- Issue
- 1
- Pages
- 46-54
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2149060182
- Cited by
- 435
- References
- 42
- FWCI
- 27.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.